While many bladder cancer patients have benefited from neoadjuvants, their application in prostate and kidney cancers is currently confined to clinical trials. Researchers at the Icahn School of Medicine at Mount Sinai investigated related neoadjuvant studies and how they might inform future study designs to benefit more patients.